Table 1.

Proteins in the literature (since 2007) that have been assayed in plasma/serum from ovarian cancer patients and have known ratios of 1 year hormone therapy compared to baseline

ProteinLog2 ratio (1 year HT/baseline)PReference
AFM0.130.00325, 7
ALCAM0.020.5012
Cathepsin L−0.39 (CTSL1)0.20 (CTSL1)19
CCL18−1.620.06018
CD14−0.0290.4112
CLU0.0870.000946
CST30.0590.0126
FBLN1−0.0321.0019
Fibrinogen0.34 (FGA)0.00056 (FGA)19
0.24 (FGB)0.06 (FGB)
FN1−0.280.003119
GRN0.0680.4212
Hemoglobin0.34 (HBA)0.45 (HBA)
0.11 (HBB)0.60 (HBB)19
0.021 (HBD)0.55 (HBD)
IGF1−0.364.81E-0513
IGF2−0.0350.369, 11, 16, 19
IGFBP10.920.000233, 10
IGFBP2−0.340.02512
IGFBP3−0.0700.03813, 17
IGFBP40.350.0106, 17
IGFBP5−0.0740.0366, 17
IGFBP60.150.0336
IGFBP7−0.200.00216
Inhibin (total)0.25 (INHBC)0.036 (INHBC)15, 19
0.38 (INHBE)0.0083 (INHBE)
ITIH40.420.0001819
LCN20.180.1511, 12
MIF−0.0410.7311, 16
MMP2−0.590.4110, 17
NOV−0.490.005312
PI30.240.08212
PPBP0.130.01412
RARRES20.150.03912
TGFB1−0.0150.4312
THBS10.230.2412
TIMP1−0.290.019
TIMP2−0.00900.86
TNFRSF21−0.110.2612
VASN−0.390.00446
VCAM1−0.0840.1710, 12
VEGF−0.81 (VEGFC)0.082 (VEGFC)14
VWF−0.0390.4412
WFDC2 (HE4)−0.0550.974, 11, 19

Abbreviation: HT, hormone therapy.